GLP-1 vs GIP: What the Difference Means for Your Weight Loss

If you have read anything about the newer weight-loss medications, you have almost certainly run into two acronyms that get used as if everyone already knows what they mean: GLP-1 and GIP. They appear together because the most effective obesity drug yet developed, tirzepatide, acts on both of them at once. But they are not interchangeable, and they are not simply two names for the same thing. They are distinct hormones, made by different cells, with overlapping but genuinely different jobs — and the story of how the field learned to combine them is one of the more interesting and unresolved chapters in modern metabolic medicine.

This article is about the hormones themselves rather than the drugs built on them, though the two are impossible to fully separate. The aim is to give you a working mental model: what GLP-1 and GIP actually are, where they come from, what each does to appetite and blood sugar, where they agree and where they diverge, and why engaging both at once turned out to matter for weight loss. For the wider picture of how this drug class works, the complete guide to GLP-1 medications and weight science sets out the full landscape; this page zooms in on the two-hormone comparison at its centre.

Two Hormones, One Job Description: The Incretins

GLP-1 and GIP belong to a small family of gut hormones called incretins. The name comes from a phenomenon that puzzled physiologists for much of the twentieth century. When you swallow a dose of glucose, your body releases substantially more insulin than it does when the same amount of glucose is delivered straight into a vein, bypassing the digestive tract. Something about food passing through the gut amplifies the insulin response. That amplification is the incretin effect, and the hormones responsible for it are the incretins.

There are two principal ones, and that is essentially the whole family as far as human metabolism is concerned. GIP — glucose-dependent insulinotropic polypeptide — was discovered first, in the early 1970s. GLP-1 — glucagon-like peptide-1 — came later. Together they account for the great majority of the incretin effect: in a healthy person, gut hormones released during a meal are responsible for somewhere around half to two-thirds of the total insulin secreted in response to that meal. Without them, the pancreas would respond far more sluggishly to food.

Both hormones share a defining safety-relevant feature: their effect on insulin is glucose-dependent. They amplify insulin release only when blood sugar is actually elevated. When glucose is normal or low, the signal switches off. This is why, as Daniel Drucker's 2018 synthesis in Cell Metabolism describes for GLP-1, incretin-based therapies carry a relatively low risk of driving blood sugar dangerously low on their own — they do not force insulin out regardless of need, the way some older diabetes drugs do. Beyond that shared logic, however, the two hormones diverge in ways that matter.

Where They Come From and What Switches Them On

The first difference is anatomical. The two hormones are made in different parts of the gut, by different cells.

GIP is secreted by K-cells, concentrated in the upper small intestine — the duodenum and proximal jejunum, the first stretch of gut that food reaches after leaving the stomach. GLP-1 is secreted by L-cells, found mostly in the lower small intestine and the colon, further downstream. Because food hits the upper gut first, GIP tends to be released slightly earlier in the digestive sequence, with GLP-1 following as nutrients travel further along.

The two also respond somewhat differently to what you eat. GIP is released strongly in response to both fat and carbohydrate. GLP-1 responds to carbohydrate, fat, and protein, and is particularly associated with the arrival of nutrients in the more distal gut. The practical upshot is that a meal triggers both hormones, but the balance and timing of the two depends on what the meal contains and how quickly it moves through the digestive tract. A foundational plain-English account of GLP-1 itself sits in what GLP-1 is, which is a useful companion to this comparison.

The Core Difference: Appetite and Body Weight

On blood sugar, GLP-1 and GIP do broadly similar things — both enhance glucose-dependent insulin secretion. The sharpest divergence is on appetite and body weight, and this is where the comparison gets genuinely interesting.

GLP-1's role in appetite is well established. It acts through several channels at once. It slows the rate at which the stomach empties, so a meal produces a longer-lasting sense of fullness. It acts on the hypothalamus — the brain's appetite-control region — to bias the system toward satiety. And, as Liselotte van Bloemendaal and colleagues showed with functional MRI in 2014, GLP-1 receptor activation reduces the response of the brain's reward circuitry to food cues, dampening the pull that food exerts on attention. Drucker's work frames GLP-1 as a multi-functional hormone that touches insulin, glucagon, gastric emptying, and central appetite all at once. This combination is precisely why it became such a productive drug target, and the mechanics for the two leading agents are laid out in how semaglutide works for weight loss.

GIP's role in appetite and weight is far less settled — and frankly confusing. For years, GIP was thought to promote fat storage. It enhances insulin secretion after fatty meals, and insulin drives nutrients into fat tissue, so the intuitive reading was that GIP helps the body lay down fat. Consistent with that, some animal studies found that blocking GIP signalling protected against weight gain. On that evidence, you would expect a weight-loss drug to want to switch GIP off, not on.

Yet the most successful obesity drug to date, tirzepatide, works in part by activating the GIP receptor. This is the paradox at the heart of the GLP-1-versus-GIP question, and it is worth stating plainly because the field has not fully resolved it: both activating and blocking the GIP receptor have shown weight-loss potential in different experimental settings. The two facts seem to contradict each other, and reconciling them is an active area of research rather than settled science.

Why Combining Them Matters: The Tirzepatide Question

The leading explanation for the GIP paradox is a phenomenon called receptor desensitisation. The idea is that sustained, strong activation of the GIP receptor may eventually cause the receptor to downregulate or become less responsive — so that continuous agonism ends up producing an effect that, functionally, resembles antagonism. In other words, hitting the receptor hard enough and long enough might be a roundabout way of turning it down. This would explain how a drug that activates GIP could produce results that earlier work expected from blocking it. It is a plausible hypothesis with experimental support, but it remains a hypothesis, and other mechanisms — including direct central effects of GIP on appetite and on nausea pathways — are also under investigation.

Whatever the mechanism, the clinical data are clear on one point: engaging both incretin pathways at once outperforms engaging GLP-1 alone. Tirzepatide is a single engineered molecule that activates both the GLP-1 and the GIP receptor — a dual agonist. In the SURMOUNT-1 trial, reported by Ania Jastreboff and colleagues in 2022, the highest tirzepatide dose produced a mean weight loss of about 21% over 72 weeks. For comparison, semaglutide — a GLP-1 agonist acting on a single receptor — produced a mean loss of about 15% over 68 weeks in the comparable STEP 1 trial reported by John Wilding and colleagues in 2021. The dual agonist, in short, did more.

What remains genuinely uncertain is why the dual molecule does more. There are two broad possibilities, and the field has not decided between them. One is that GIP agonism adds something GLP-1 cannot — a distinct, additive contribution to appetite suppression or metabolic effect. The other is that the dual molecule simply achieves a different and more favourable overall signalling profile, perhaps allowing higher effective dosing or smoother tolerability, rather than GIP contributing a separable effect of its own. Both readings fit the data. The practical result is the same regardless: two receptors engaged together outperform one. The head-to-head detail for people weighing the two drugs is set out in the tirzepatide versus semaglutide comparison, and the mechanism of the dual agonist specifically in how tirzepatide works.

GLP-1 vs GIP at a Glance

The table below summarises the comparison at the level of the hormones themselves. The two share a family and a glucose-dependent logic, but differ in origin, timing, and — most importantly — in how clearly their role in body weight is understood.

	GLP-1	GIP
Full name	Glucagon-like peptide-1	Glucose-dependent insulinotropic polypeptide
Secreting cells	L-cells (distal small intestine, colon)	K-cells (upper small intestine)
Insulin effect	Glucose-dependent enhancement	Glucose-dependent enhancement
Glucagon	Suppresses it	Tends to raise it
Gastric emptying	Slows it	Little effect
Appetite / brain	Clearly reduces appetite; dampens food reward	Role unclear; both activating and blocking show weight effects
Drug example	Semaglutide (single agonist)	Combined with GLP-1 in tirzepatide (dual agonist)

One row in that table deserves a note, because it is an under-appreciated difference. On glucagon — the hormone that raises blood sugar by prompting the liver to release stored glucose — the two incretins actually point in opposite directions. GLP-1 suppresses glucagon, which helps lower blood sugar from a second angle. GIP, by contrast, tends to raise glucagon. In a healthy person these effects are part of a balanced system; in the context of a dual-agonist drug, they are one more reason the net effect of combining the two is not a simple sum of their parts.

What This Means for Your Weight Loss

If you are taking or considering one of these medications, the GLP-1-versus-GIP distinction is not just trivia. It maps onto a real choice between drug classes. Single-agonist GLP-1 medications such as semaglutide engage one of the two incretin pathways. Dual-agonist medications such as tirzepatide engage both, and in trials have produced larger average weight loss. That difference in mechanism is the biological reason behind the difference in results — and behind the fact that the same molecule appears under different brand names for diabetes and for weight, a source of considerable confusion unpacked in Mounjaro versus Zepbound.

It is worth being honest about the limits of what the hormone story can tell you, though. Larger average weight loss in a trial does not mean tirzepatide is the right choice for every individual. Tolerability, side effects, cost, insurance coverage, supply, and the specific clinical situation all bear on the decision, and averages conceal wide individual variation — some people respond strongly to one agent and modestly to another for reasons that are not yet predictable in advance. The mechanism explains the population-level pattern; it does not pick your medication for you. That is a decision for a prescriber, not a comparison table.

It also helps to hold the appetite story in its proper context. GLP-1 and GIP are signals layered on top of a deeper system that defends body weight. Priya Sumithran and colleagues showed in 2011 that after weight loss, the body's appetite-regulating hormones remain dysregulated for at least a year in the direction that favours regain — hunger drivers elevated, satiety signals suppressed. Masayasu Kojima's discovery of ghrelin in 1999 identified the loudest of those hunger drivers, and Nora Volkow's imaging work has documented how food engages the same reward circuitry as other reinforcers. What incretin-based drugs do is counter that defended biology for as long as they are present, which is why they tend to be most useful understood as ongoing management of a chronic condition rather than a short course. The broader hormonal map — and where these two incretins sit within it — is collected on the GLP-1 science hub.

The short version, then: GLP-1 and GIP are the body's two main incretins, both released after meals, both amplifying insulin only when blood sugar is high. GLP-1 has a clear, well-mapped role in suppressing appetite. GIP's role in weight is genuinely unsettled — paradoxically, both turning it on and turning it off can produce weight loss. And the practical lesson of the last few years is that engaging both pathways together, as tirzepatide does, outperforms engaging GLP-1 alone, even though the field is still working out exactly why. That unresolved "why" is not a gap in the marketing; it is an honest reflection of where the science currently stands.